Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 29, Issue 3, Pages 310-313Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2017.1360991
Keywords
Carvedilol; rosacea; flushing; erythema; long-term treatment
Categories
Funding
- AbbVie
- Bayer Healthcare
- Galderma
- La Roche-Posay
Ask authors/readers for more resources
Background: The treatment of persistent erythema and flushing episodes in patients with rosacea remains a clinical challenge. A possible therapeutic option could be the use of antihypertensive drugs. Objectives: We therefore evaluated the effect of the non-selective beta-blocker carvedilol in five Caucasian patients. Methods: In a monocentric retrospective case study, the patients were treated with carvedilol titrated up to 12.5mg twice a day over at least six months. Patients self assessment (PSA), clinicians erythema assessment (CEA), and the patients levels of embarrassment and satisfaction were performed by questionaires. Results: The CEA grade description as well as the PSA grade description decreased remarkably in all five patients. Furthermore, all patients reported to have a major improvement of their level of satisfaction and no feelings of embarrassment anymore. Conclusions: These findings demonstrate that facial flushing and persistent erythema can be effectively treated by carvedilol long-term with a fast onset of improvement in a dose well tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available